Unadjusted analyses of the combined trials demonstrated that CD8+ cell density was significantly associated with stage II versus III disease, tumour right-sidedness, MMR-D or POLE mutation, lack of chromosomal instability (CIN), BRAF mutation and absence of disease recurrence and death, but not age, sex, pT stage or KRAS mutation (Table S6). The gene discussed is CD8A; the disease is neoplasm.